Social media success in consumer marketing has advanced beyond counting fans and followers. Today it's all about shares, retweets and links that indicate real consumer engagement with brands....
Startup Clinical Ink said that it's in the midst of a pilot clinical study that incorporates medical device data that's collected through a smartphone app with biopharma Novartis and contract research organization PPD. The trial incorporates medical device connectivity that's provided by Clinical Ink and powered by Qualcomm's 2net Mobile Platform.
The launch for Glatopa, the new generic of Teva's Copaxone from Novartis' Sandoz, is still in the very early going. But so far, things look good--very good.
With all the excitement about Novartis' new heart failure drug Entresto, the usual question that follows an FDA approval--how will they actually sell it--might seem irrelevant. But the former LCZ696's path to blockbuster sales isn't without its obstacles, and the Swiss drugmaker isn't leaving much to chance.
Novartis CEO Joe Jimenez said in March the company would have another go at significant cost cuts in the wake of its asset swap with GlaxoSmithKline. Manufacturing was one area where it expected to tighten up, and a plant in India is now on the chopping block along with 170 jobs.
Novartis has said it's planning to offer an outcomes-based plan for its new blockbuster-in-the-making to secure payers' favor. But skeptics see some kinks in the plan--and the CMO at leading PBM Express is one of them.
It was a hotly anticipated pipeline drug. Now, Novartis' heart failure remedy Entresto is a hot new approval. The FDA gave its blessing 6 weeks early, and now the former LCZ696 can get ready to roll.
The FDA has approved Novartis' big 2015 blockbuster, the heart failure drug Entresto, better known in development circles as LCZ696.
Novartis has opened a new front in its push into digital health. The latest move sees the Big Pharma bring its navigation app for visually impaired people to Apple and Google's smartwatch platforms.
Out with the old guard, in with the new. In another sign that Big Biotech is elbowing into the top levels of pharma, Celgene has agreed to buy Merck & Co.'s old campus in Summit, NJ, adding the sprawling 1.3-million-square-foot complex to its already growing operations in the city.